Posts Tagged management

REVA Medical Inc Institutional Investors Commit to

Monday, March 19th, 2012 | Permalink

Elliott Management, a New York investment fund with assets under management of approximately US$19.2 billion, and current shareholders including Medtronic, Inc., the world’s largest medical device manufacturer, entered into agreements to purchase the CDIs and shares. Each purchaser independently participated in … The REVA Medical, Inc. logo is available at http ://www.globenewswire.com/newsroom/prs/?pkgid=8505. About M.M. Dillon & Co. M.M. Dillon is a …

Continue Reading:
REVA Medical Inc Institutional Investors Commit to

FDA Clears All-in-One Reconstitution/Administration Syringe for Xyntha

Tuesday, November 2nd, 2010 | Permalink

FDA Clears All-in-One Reconstitution/Administration Syringe for Xyntha Information from Industry Four experts review metastatic GIST case Connect with the GIST Exchange to view a new program on diagnosising and treating metastatic progressive gastrointestinal stromal tumors (GIST) in a 55-year-old male. Review case study August 10, 2010 — The US Food and Drug Administration (FDA) has granted 510(k) clearance for a device (Prefilled Dual-Chamber Syringe; Pfizer, Inc) used to reconstitute and administer antihemophilic factor (recombinant) plasma/albumin-free intravenous infusion (Xyntha; Pfizer) in patients with hemophilia A. The all-in-one syringe is the first to supply freeze-dried albumin-free recombinant factor VIII and also the diluent (0.9% sodium chloride), thereby eliminating the reconstitution transfer step and improving patient convenience.

Read More:
FDA Clears All-in-One Reconstitution/Administration Syringe for Xyntha

Contact Us

Click or drag a file to this area to upload.